Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Ash 2019 – for Car-T the bispecific antibody threat is real
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
AACR 2019 – Baylor sets the benchmark for Bellicum
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
